Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
about
Bisphosphonates and other bone agents for breast cancerPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerBisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceBisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trialsZoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysisMinimal residual disease and circulating tumor cells in breast cancerOmentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progressionBone-targeted therapy in metastatic breast cancer - all well-established knowledge?Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasisEnhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.A Novel Prothrombotic Pathway in Systemic Sclerosis Patients: Possible Role of Bisphosphonate-Activated γδ T Cells.Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patientsDisseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention studyBone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patientsPreclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastasesAdjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Prevention of bone metastases and management of bone health in early breast cancer.Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Adjuvant bisphosphonates in breast cancer treatmentAdjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer PatientsBisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyondZoledronic acid in breast cancer: latest findings and interpretationsTreatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticePrevention of Bone Metastases in Breast Cancer Patients. Therapeutic PerspectivesCan Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian GuidelineBasal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
P2860
Q24203656-4CB66DBB-E7B9-44AF-A2BC-BF36DB741947Q26746212-23CF1318-D9C7-480F-A015-C75FD5BECC49Q26795493-19307ADD-7B60-4124-A3A5-8A580CD359F6Q26861586-B44597B8-2D69-4528-B506-2459413DE2E8Q26861745-5E9E8B3F-2E1A-4226-9F09-04A4F1EE45DAQ27010152-9A37E7CE-3B10-47F9-8E00-F5C785F1A45AQ28076686-4FA2B601-ED2B-4BD7-9223-035FE1653F71Q28087676-91AC0765-500A-4E70-B422-0B8E17EDB197Q28551320-D7AAD639-66DA-4E14-8A4D-4B43415166D5Q30439048-0C645A2A-2452-469C-8173-061CB119C0C7Q33587199-3C423EB8-F448-4ABB-AC2B-2664D702BBF1Q33739204-71904565-3409-41D8-93E8-176C3659008FQ33786905-56501298-1857-4835-86ED-601AD13C9C3BQ33801735-9C7FC379-1F7C-4AAD-AA4B-7F63074A21F2Q34024176-DCD79C3C-CF03-4CEE-AFE6-871036DBF40DQ34075052-F0735B11-AD85-4FDC-B1C4-74B2AB209A2BQ34145863-A8516B17-BBBA-40B9-88CE-0FE7664698AAQ34148693-8A59C7A3-DA00-4973-AB2A-9C71C2CAE310Q34232366-D1817323-154F-41B7-A971-D20B6852195FQ34348233-90C9A4E4-0196-477E-92A7-C410EC754775Q34441622-13CAF2BB-5D4A-4FAD-A60B-0FB3D0E6C9FAQ34468675-A9A0A403-E091-4386-864C-428A2747003BQ34520174-DB0FD73E-5D21-4BE7-BFC5-F7698B3C363BQ34547042-0D8BB8A6-41AB-41B6-9D01-D27C01DE774DQ34561406-2A47253C-E104-4591-89FA-061C4842494BQ34583705-F35BE7E8-3CDE-4D76-BC88-0E2A12294903Q34613485-9AA89BD2-ACE5-4519-9797-919EC1D0F483Q34613492-23BB08D4-B38E-422F-98CB-57D68D8C6F1FQ34896573-3FBA597A-C703-4179-B95F-728D11D4C356Q34939979-214A6F05-5976-46AC-96D5-1ABDFD9DF0F3Q35066934-08025361-EDAA-4EE4-8719-FF17D3907D9FQ35095543-0E6EA233-8A30-459F-B1AC-30CD4F28DD45Q35172721-D7EA798F-FAF0-48FF-846E-C96FE6E9F1ECQ35239617-AF6E10E9-3C67-4A3E-B755-E6AB7565654EQ35534524-15BD3DDD-06FC-45BF-BA2E-6DD89BC6D1F4Q35667196-800D76B2-AD6B-488A-976C-1CCB91C38E11Q35667318-8EC9206D-D625-43F6-8B19-5F5AA5A90FCCQ35750453-A2BC084C-AF49-47CF-BFDC-EC1350C6F47FQ35750472-06812753-0305-48FE-9876-BFD40612288DQ35832193-6998F43B-5790-45E3-93CA-0903022F64FD
P2860
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.
@ast
Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.
@en
type
label
Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.
@ast
Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.
@en
prefLabel
Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.
@ast
Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.
@en
P2093
P2860
P1433
P1476
Effect of zoledronic acid on d ...... el, randomised, phase 2 trial.
@en
P2093
Cynthia Ma
Imran Zoberi
Jill Dietz
Joanne Mortimer
Katherine Weilbaecher
Kathryn Diemer
Kathryn Trinkaus
Lourdes Ylagan
P2860
P304
P356
10.1016/S1470-2045(10)70054-1
P577
2010-03-31T00:00:00Z